CN104693285A - Vascular-endothelial-growth-factor-C antagonistic polypeptide and application thereof - Google Patents
Vascular-endothelial-growth-factor-C antagonistic polypeptide and application thereof Download PDFInfo
- Publication number
- CN104693285A CN104693285A CN201510157266.1A CN201510157266A CN104693285A CN 104693285 A CN104693285 A CN 104693285A CN 201510157266 A CN201510157266 A CN 201510157266A CN 104693285 A CN104693285 A CN 104693285A
- Authority
- CN
- China
- Prior art keywords
- vascular endothelial
- endothelial growth
- polypeptide
- growth factor
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of drugs, in particular to polypeptide for suppressing vascular endothelial growth factors C and treating the acute lymphocytic leukemia. The sequence of the polypeptide is NHISTPQCQGLSKPHKITV and is a brand new sequence. By means of the polypeptide, the vascular endothelial growth factors C can be suppressed out of a body at a 1-micromole level, the tumor-bearing mice survival rate can be increased in an in-vivo test, and the potential new drug development value is achieved.
Description
Technical field
The present invention relates to vascular endothelial growth factor C antagonism polypeptide and application thereof, be specifically related to that there is suppression vascular endothelial growth factor C, the polypeptide for the treatment of acute lymphoblastic leukemia.
Background technology
Acute lymphoblastic leukemia (ALL) is a kind of Progressive symmetric erythrokeratodermia malignant disease, it is characterized by a large amount of to be similar to lymphoblastic neocyte.These cells can find in blood, marrow, lymphoglandula, spleen and other organ.Acute lymphoblastic leukemia accounts for 80% of acute leukemia, and sickness rate peak is between 3 years old to 7 years old.To the maximum threat of acute lymphoblastic leukemia patient be diffusion and transfer.How eliminating the distant metastasis of certain cancer or prevent recurrence, is indispensable integral part in cancer treatment method, is also the treatment acute lymphoblastic leukemia hot issue inquired at present.
Lymph is the colourless transparent liquid in humans and animals body, includes lymphocyte, is formed after infiltrating lymphatic vessel by tissue juice.Lymphatic vessel is the pipe that structure follows vein similar, is distributed in each portion of whole body.The different lymphocyte produced in acute lymphoblastic leukemia patient Lymphoid tissue circulates at intralymphatic, finally flows into vein, enters blood.If suppress vasculolymphatic generation, just can suppress the migration of abnormal lymphocytes, enter in blood tissues, reduce migration and the disease palindromia of leukemia cell.Therefore, the transfer of vasculolymphatic generation to leukemia cell has vital effect.
The important cytokine that VEGF-C (VEGF-C) regulates lymphatic vessel to generate, by the combination with VEGFR3, there is the complicated cascade effect of biochemical signals in VEGF-C, causes lumen to be formed and be divided into ripe lymphatic vessel.Therefore, the migration of VEGF-C and leukemia cell is closely related.Suppress VEGF-C, the combination of VEGF-C and VEGFR3 can be suppressed, suppress ripe lymphatic vessel to be formed, thus suppress the transfer of leukemia cell, effectively can reduce the symptom of disease, control advancing of disease.
At present, do not have the VEGF-C antagonism polypeptide of ripe exploitation to come out, be used for the treatment of acute lymphoblastic leukemia.
Vascular endothelial growth factor C antagonism polypeptide in this patent has proved in acute lymphoblastic leukemia effective, has the prospect developed in other tumor models.
Summary of the invention
goal of the invention
The invention provides brand-new sequence, this sequence is vascular endothelial growth factor C antagonist, has good curative effect to acute lymphoblastic leukemia.
technical scheme
vascular endothelial growth factor C antagonism polypeptide, is characterized in that its sequence is NHISTPQCQGLSKPHKITV.
The application of vascular endothelial growth factor C antagonism polypeptide in treatment acute lymphoblastic leukemia medicine.
beneficial effect
Utilize solid-phase synthesis chemosynthesis vascular endothelial growth factor C antagonism polypeptide, this polypeptide has brand-new sequence, and this polypeptide can vitro inhibition vascular endothelial growth factor C, treatment acute lymphoblastic leukemia.The vascular endothelial growth factor C antagonism polypeptide that we find can suppress lymphatic endothelium proliferation activity simultaneously, and improves tumor-bearing mice survival rate in testing in vivo, has potential new drug development value.
Embodiment
Embodiment 1
Vascular endothelial growth factor C antagonism polypeptide is on the impact of extracorporeal blood vessel endothelial cell growth factor (ECGF) C acceptor and vascular endothelial growth factor C avidity.
By people's lymphatic endothelium of logarithmic growth, with 1.0 × 10
5add in 96 well culture plates, cultivate 24h, experimental port, positive drug control hole add Experimental agents vascular endothelial growth factor C antagonism polypeptide (the raw work synthesis in Shanghai) and the positive control medicine vincristine(VCR) of different concns respectively; Blank group adds the solvent of same volume, adds meanwhile
125the vascular endothelial growth factor C of I mark.Five multiple holes are established in every hole, cultivate 48h.Wash away supernatant liquor, use-liquid scintillation counter calculates intensity of radioactivity, and judge the bonding force of vascular endothelial growth factor C acceptor and vascular endothelial growth factor C, intensity of radioactivity intensity is stronger, and in conjunction with more, otherwise intensity of radioactivity intensity is more weak, in conjunction with fewer.Result shows, with vascular endothelial growth factor C antagonism polypeptide concentration increase, is combined with vascular endothelial growth factor C and increases gradually, illustrate and vascular endothelial growth factor C binding ability constantly reduce with the increase of drug level.
Embodiment 2
Vascular endothelial growth factor C antagonism polypeptide is to the growth of vitro culture of human lymphatic endothelium and survival IC50.
Adopt MTT colorimetry.By people's lymphatic endothelium of logarithmic growth, with 1.0 × 10
5add in 96 well culture plates, cultivate 24h, experimental port, positive drug control hole add Experimental agents vascular endothelial growth factor C antagonism polypeptide and the positive control medicine taxol of different concns respectively; Blank group adds the solvent of same volume.Five multiple holes are established in every hole, cultivate 48h, respectively 0h, 2h, 8h, 14h, 20h, 24h, 36h, the every hole of 48h adds MTT, after effect 4h, add DMSO, hatch 30min, absorbance A value is measured, by formula people lymphatic endothelium growth inhibition ratio=(1-experimental group light absorption value/control group light absorption value) × 100% at microplate reader 620nm place.The IC50 calculating Experimental agents is 21.92 μMs.
Embodiment 3
With vigor in the body of tumor model detection vascular endothelial growth factor C antagonism polypeptide.
Set up U937 tumor model, positive control medicine taxol; Blank group adds the solvent of same volume, and experimental group establishes 3 dosage: 0.75,1.5,3 mg/Kg.After 21 days, observe mouse survival quantity, calculate survival rate.Result shows, and vascular endothelial growth factor C antagonism polypeptide can protect small white mouse effectively, and improve the survival rate of tumor-bearing mice, survival rate reaches 63.0%.
SEQUENCE LISTING
Pu Luoda bio tech ltd, <110> Suzhou
<120> vascular endothelial growth factor C antagonism polypeptide and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 19
<212> PRT
<213> artificial sequence
<400> 1
Asn His Ile Ser Thr Pro Gln Cys Gln Gly Leu Ser Lys Pro His Lys
1 5 10 15
Ile Thr Val
Claims (2)
1. vascular endothelial growth factor C antagonism polypeptide, is characterized in that its sequence is NHISTPQCQGLSKPHKITV.
2. the application of vascular endothelial growth factor C antagonism polypeptide in treatment acute lymphoblastic leukemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510157266.1A CN104693285A (en) | 2015-04-06 | 2015-04-06 | Vascular-endothelial-growth-factor-C antagonistic polypeptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510157266.1A CN104693285A (en) | 2015-04-06 | 2015-04-06 | Vascular-endothelial-growth-factor-C antagonistic polypeptide and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104693285A true CN104693285A (en) | 2015-06-10 |
Family
ID=53340872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510157266.1A Pending CN104693285A (en) | 2015-04-06 | 2015-04-06 | Vascular-endothelial-growth-factor-C antagonistic polypeptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104693285A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330664A (en) * | 1998-09-30 | 2002-01-09 | 路德维格癌症研究所 | Platelet-derived growth factor C, DNA coding therefor and uses thereof |
| CN101528235A (en) * | 2006-10-27 | 2009-09-09 | 詹森药业有限公司 | Vegfr3 inhibitors |
-
2015
- 2015-04-06 CN CN201510157266.1A patent/CN104693285A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330664A (en) * | 1998-09-30 | 2002-01-09 | 路德维格癌症研究所 | Platelet-derived growth factor C, DNA coding therefor and uses thereof |
| CN101528235A (en) * | 2006-10-27 | 2009-09-09 | 詹森药业有限公司 | Vegfr3 inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| 陈敬德等: "贝伐单抗联合化疗药物诱导白血病细胞株凋亡的实验研究", 《白血病•淋巴瘤》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102488890A (en) | Application of integrin blocker polypeptide AP25 in preparation of medicines for treating tumor | |
| CN101612400A (en) | 1 application of receptor antagonist in antitumor of angiotensin | |
| CN109568299A (en) | Ambroxol purposes in preparing tumor chemotherapeutic drug Synergistic preparations | |
| CN102850443A (en) | Integrin blocker polypeptides and application thereof | |
| CN104398526A (en) | Application of triptolide and tripterine in preparation of antitumor drugs | |
| CN104693285A (en) | Vascular-endothelial-growth-factor-C antagonistic polypeptide and application thereof | |
| CN103933048A (en) | Applications of ursolic acid derivatives in preparation of drug for preventing and treating tumor metastasis | |
| CN104693286A (en) | Vascular endothelial growth factor C antagonistic polypeptide and application thereof | |
| CN104744565A (en) | Antagonistic polypeptide for vascular endothelial growth factor C and application of antagonistic polypeptides | |
| CN101502607B (en) | Cordyceps sinensis and mushroom composition, Cordyceps sinensis and mushroom polysaccharide oral liquid, and preparation method thereof | |
| CN102357123B (en) | Application of herba dicranostigmae alcohol extract in preparing medicines for resisting melanoma transfer | |
| CN104586847A (en) | Pharmaceutical composition using liensinine to work in coordination with paclitaxel for chemotherapy and application method of pharmaceutical composition | |
| CN103923184A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN103739680B (en) | A kind of anti-adhesion spot kinase polypeptide and application thereof | |
| CN104693281A (en) | Angiostatin activating agent polypeptide and application thereof | |
| CN103142584B (en) | Application of polysubstituted 5-hydroxypyrrolidone compounds in preparation of antitumor medicines | |
| CN103923187A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN104045693B (en) | A kind of about PER2 protein agonist polypeptide and application thereof | |
| CN104694520A (en) | Hydrolyzed profibrinolysin polypeptide and application thereof | |
| CN103739678B (en) | Anti-adhesion spot kinase polypeptide and application thereof | |
| CN102432671A (en) | Targeting polypeptide SPSCVLP capable of inhibiting growth and transfer of liver cancer and application thereof | |
| CN104693284A (en) | Platelet-derived-growth-factor antagonistic polypeptide and application thereof | |
| CN106491603A (en) | A kind of pharmaceutical composition and its application containing capsaicin and Sorafenib | |
| CN104693289A (en) | Tight-junction protein inhibitor polypeptide and application thereof | |
| CN106943404B (en) | Anticancer pharmaceutical composition containing vincristine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150610 |